Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | ILK | Q13418 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 3/20 | 0.42 |
| ▸ | HIPK1 | Q86Z02 | 3/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.42 |
| ▸ | HIPK3 | Q9H422 | 3/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729450 | 0.79 | AKT2 (0.53) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL3510580 | 0.79 | AKT2 (0.53) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL29590240 | 0.78 | CCR1 (0.54) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL13464878 | 0.78 | AKT2 (0.52) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL15326994 | 0.78 | CCR1 (0.54) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL15671554 | 0.75 | AKT1 (0.48) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL17032665 | 0.74 | AKT1 (0.47) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL30061986 | 0.74 | CTSS (0.48) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL17031771 | 0.74 | MAPK8 (0.49) | AKT2AKT1IRAK4ILKCLK2 | |
| SCHEMBL14328175 | 0.74 | AKT1 (0.47) | AKT2AKT1IRAK4ILKCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | AKT2 875/4885AKT1 1304/4885IRAK4 605/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | AKT2 875/4885AKT1 1304/4885IRAK4 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.